TLOG — Tetralogic Pharmaceuticals Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $24.92m
Annual income statement for Tetralogic Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2011 December 31st | 2012 December 31st | 2013 December 31st | 2014 December 31st | 2015 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 18.9 | 16.2 | 18 | 33.8 | 45 |
Operating Profit | -18.9 | -16.2 | -18 | -33.8 | -45 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -18.9 | -16.2 | -20 | -36 | -49.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -18.9 | -16.2 | -20 | -36 | -49.7 |
Net Income Before Extraordinary Items | |||||
Net Income | -18.9 | -16.2 | -20 | -36 | -49.7 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -22.2 | -19.7 | -23.2 | -36 | -49.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.05 | -0.931 | -1.1 | -1.61 | -1.39 |
Dividends per Share |